OS Therapies, Inc. (NYSE-A: OSTX), a leader in gene-edited, listeria-based cancer immunotherapies, has successfully completed a registered direct offering, raising $5.25 million. The offering involved the sale of common stock and pre-funded warrants, primarily to high-net-worth investors who have previously participated in the company's financing rounds. Each investor received shares at a price of $1.40 per share or pre-funded warrants at $1.399, along with warrants to purchase additional shares at the same price. The offering is expected to provide the company with a cash runway into 2027, bolstered by anticipated non-dilutive VAT refunds and R&D tax credits from its U.K. subsidiary, estimated at around $4 million. This funding will support OS Therapies as it approaches critical regulatory milestones for its lead product, OST-HER2, aimed at treating osteosarcoma. The company expects to receive approvals in the U.S., U.K., and Europe for OST-HER2 in the latter half of 2026. The successful completion of this offering, along with the expected non-dilutive funding, positions OS Therapies favorably as it advances its clinical development and prepares for upcoming regulatory interactions with agencies such as the FDA and EMA.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.